Cephalochromin, a FabI-directed antibacterial of microbial origin

Microorganisms produce many kinds of Antibiotics which function in an antagonistic capacity in nature where they have much competition. Bacterial enoyl-acyl carrier protein (ACP) reductase (FabI) has been demonstrated to be an Antibacterial target. However, no FabI-directed Antibiotic of microbial origin has been reported so far. In this study, we found that cephalochromin with a naphtho-gamma-pyrone skeleton, a Fungal secondary metabolite, inhibited FabI of Staphylococcus aureus and Escherichia coli with IC50 of 1.9 and 1.8 microM, respectively. The methylether derivatives of cephalochromin, however, did not inhibit FabI. The FabI-inhibitory activities of cephalochromin and its derivatives well correlated with Antibacterial activity as well as the inhibition of cellular fatty acid biosynthesis. Furthermore, FabI-overexpressing S. aureus exhibited reduced susceptibility to cephalochromin compared to the wild-type strain, demonstrating that the mode of Antibacterial action of cephalochromin is via the inhibition of FabI. These results indicate that cephalochromin is the first FabI-directed Antibacterial of microbial origin and may have the potential for further Antibacterial development.